Pancrelipase Improves Stool Frequency and Consistency in EPI
Participants had a 5-day placebo run-in period and then were randomly assigned to pancrelipase (72,000 LU/meal; 36,000 LU/snack) or placebo for a 7-day, double-blind period.
Participants had a 5-day placebo run-in period and then were randomly assigned to pancrelipase (72,000 LU/meal; 36,000 LU/snack) or placebo for a 7-day, double-blind period.
This week, news of the FDA’s vote on AMX0035, the novel ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares.
Sucraid is an oral enzyme replacement therapy of the genetically determined sucrase deficiency.
The approval was based on data from the phase 3 TOPAZ-1 trial.
Stay up-to-date on the latest drugs in development.
The sBLA was supported by data from the phase 3 TOPAZ-1 trial.
Guideline revised to synthesize current best practices in the management of Barrett esophagus
GLP-1 RA treatment linked to increased risk, especially in trials for weight loss, and with higher doses and longer duration of use
Overall survival, progression-free survival prolonged in those receiving durvalumab versus placebo in addition to gemcitabine and cisplatin